BSEBoard Meeting6d ago · 2 Nov 2026, 02:43 pm

Outcome of the Board Meeting for the Quarter and half year ended September 30 , 2026.

Procter & Gamble Health Ltd · 500126

✦ AI SummaryResults

Procter & Gamble Health Ltd has announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company's revenue from operations was ₹38.249 lakhs, and its total income was ₹36.371 lakhs. The company's expenses included cost of materials consumed, purchases of stock-in-trade, changes in inventories of finished goods, work-in-progress and stock in trade, employee benefits expenses, depreciation and amortisation expenses, and finance costs.

Analysis Scores

Earnings Impact6/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Procter & Gamble Health Ltd - 500126 - Board Meeting Outcome for Outcome For The Board Meeting Held On November 2, 2026

Attachments (1)

📄

46cbce9e-e135-4119-9628-8c9a1c479cd1.pdf

pdf

Download →
View document text
November 2, 2026 To, To, The Corporate Relations Department The Listing Department The BSE Limited The National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400001. Mumbai – 400051 Ref:- Scrip Code:- 500126 Ref:- Symbol:- PGHL Dear Sir / Madam, Sub: Unaudited Financial Results for the quarter and half year ended September 30, 2026 We are pleased to inform you that at the meeting of the Board of Directors of the Company held today (commenced at 11:43 A.M. (IST) and ended at 02:28 P.M.), the Unaudited Financial Results along with the Statement of Assets and Liabilities and Statement of Cash flows for the quarter and half year ended September 30, 2026 were approved. We are enclosing herewith the following: a. Unaudited Financial Results along with the Statement of Assets and Liabilities and Statement of Cash flows for the quarter and half year ended September 30, 2026; b. Limited Review Report, in respect of the Unaudited Financial Results for the quarter ended and half year September 30, 2026, as furnished by the Statutory Auditors of the Company; Kindly take the same on record. Thanking you. For Procter & Gamble Health Limited Flavia Machado Authorized Signatory HARIBHAKTI & CO. LLP Chartered Accountants Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended) To the Board of Directors Procter & Gamble Health Limited 1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended September 30, 2026 and year to date results for the period from April 1, 2026 to September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Haribhakti & Co. LLP, Chartered Accountants (LLPIN: AAC·37681 Registered office: 904A, 9th Floor, R Square, Andheri•Kurla Road, Near Chakala Metro Station, J. B. Nagar, .YL!mbai-400059. www.haribhakti.co.in I info@haribhakti.co.in I Tel: +91 22 66n 9998 Other offices: Ahmedabad, Benaaluru, Chennai, Kotkata, New Delhi, Pune, Rajkot, Vadodara. HARIBHAKTI & CO. LLP Chartered Accountants 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Haribhakti ft Co. LLP Chartered Accountants ICAI Firm Registration No.103523W /W100048 ISuman~nde Membership No.: 034828 UDIN: 2603'-ii2.8kLT SStJLJ~ (?.., Place: Mumbai Date: November 02, 2026 Continuation Sheet PROCTER & GAMBLE HEALTH LIMITED A;egd, Office; P&G Plaza. Cardinal Gr'aclas Road, Chakala, Andheri (El, Mumbai; 400 09'9. CIN No. L99999MH1967PLC0137 26. emall: lnvertOr'll:r'levance.iml!)pg.ccm STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026 (f In l1khs) (I) 12) (3) (C) (SJ (6) Three months Pr'eteding Three Cout.spond•nc SI~ "1onths ended Corresponding Six Previous Year Sr. Particulars ended months ended Thre11 months ended 30th September month$ ended ended No. 30th $epte,nber 30th June 2026 30th September 2026 10th September 31st March io:i?6 2026 202S 202s (Unoudlted) (Unaudited) (Unaudited) (URiludlted) {Unaudited} (.,udited) 1. Revenue from Operations 38 249 36 371 32492 74'20 66366 140 797 2. Other fncome 389 388 495 777 898 I 734 ]. Total Income t1+2) 31631 36 7S9 32 917 7S 397 "26< U253l Expenws a) Cost of materials consumed 7169 8031 7 813 15 200 13 767 30733 b) Purchases of stock-ln-trade (Traded goods;) 3144 24S6 l 064 5 600 349S 7 058 cl Ctianges in Inventories of flnrshed goods,work-in-i:irogress and stock in trade 244 ( 86S) (2 037) (621) 11023) (1283) d) Employee be11el'its e>epenses S 377 6039 5 388 11416 10989 22 256 e) Oepreclation and amortisation expenses 608 602 608 1210 1152 2 359 f) Finance costs 13 14 12 27 24 ss g) Other expenses 7 078 10750 8 231' 17 828 18077 36367 Total uo.nn.1 (41 23633 27027 ZI OIS S0'6O CHll 97 5c5 5. Proftt before exceptlonal items and tax (3,-4) 1500S 9732 11902 24737 20783 44986 6. Add: Except tonal item (refer note?) 3180 3180 7. Profit before tu {S+6} lSOOS 12 912 11902 27917 20713 44916 8. rax expenses a) Current Tax 3 595 3103 3054 6 698 S 348 11082 b) Deferred fax Charge/ (Credit) 2S9 194 ( 6) 453 I 37J 446 <:)Adjustment of tax relating to earlier periods 767 T01al tax upensas ns• 3297 3 04ll 7151 5311 12 29S N•t P,ofh. for the Deriod / YHr (1..a, 11151 9615 IU• zo 766 15472 32 691 10. Other Comprehensive Income Items that will not be recla.»ified to profit or loss I. Re-measurement gains/ {!osses) on defined benefit plans ( 127) 41 323 ( 861 236 I 311 if.Income taii: effect on above 32 ( 10) (81) 22 (59) 10 Other Comprehen:srve lnc:ome, r,et of tilx ( 9SI 31 2•2 (6<) 177 ( 21) IL Total Comprehensive Income for the oerfod / vur (9+101 110S6 96<6 ,o96 20702 32 663 15 " ' 12. Paid-up equity snare capital {fac.e Value "I: 10/· each) 1660 1660 1660 1660 1660 1660 13. Otherequil)I so 795 14. Eamfngs Ptl' equity :shar!' {of"-10/· each) -inot annuallsed) {.i) Basic and Diluted lin ") {before exceptional Items) • 67.18 * 38.77 '53.34 • 105.94 93.21 196.94 (b) Bask and Oiluted {in ,) (after exceptional ltems} • 67.18 • 57.92 '53.34 • 125.09 93.21 196.94 PROCTER & GAMBLE HEALTH LIMITED Regd. Office: P&G Plaza, Ca,dinal Gracias Road, Chak.ala, Andheri (El, Mumbai: 400 099. CIN No. L99999MH1967PLC013726, amail: investors;rievance.im@pg.com Notes: 1. The above Una1idi1ed Financial Results have been reviewed by the Audit Commfttee and approved by the Soard of Ojrectors of the Company at thei, tespective meetmgs he!d on November 2, 2026 and have been subjeded to a limfted review by the Statutoty Auditors of the Companv.These flnancial results are prepared and publfshed in accordance with Regulation 33 of the SEBI (Listing Oblfgatfons and Dis.closure Reqi;trements) Reglllatlons, WlS, as amended and expressed "Unmod{fied" com:h.nion. 2. This Statement has been prepared in accordance with the Companies ("In [Showing first 8,000 characters — download PDF for full document]